Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony chłoniak pierwotny ośrodkowego układu nerwowego typu CD20+ (rodzaj nowotworu limfatycznego)
- •Wcześniejsze leczenie chemioterapią wysokodawkową na bazie metotreksatu, z or bez radioterapii mózgu
- •Odpowiedź na leczenie - całkowite zniknięcie raka lub znaczne zmniejszenie guza
- •Badanie MRI mózgu w ciągu 30 dni przed włączeniem do badania
- •Jeśli przed leczeniem były komórki raka w płynie mózgowo-rdzeniowym lub zapalenie oczu, muszą być powtórzone badania potwierdzające całkowitą eliminację
- •Stan ogólny pacjenta na poziomie co najmniej 60% wydolności (skala Karnofskiego)
- •Włączenie do badania w ciągu 75 dni od zakończenia leczenia początkowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic
Cleveland, United States
Providence Health & Services; Providence Neurological Specialties
Portland, United States
Pennsylvania State University
Hershey, United States
University of Vermont
Burlington, United States
University of Virginia
Charlottesville, United States
Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute
Seattle, United States
Trial contact
Tiffany Gervasi-Follmar
Holly Marino
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.